uniQure (NASDAQ:QURE) Shares Gap Up – Here’s Why

uniQure N.V. (NASDAQ:QURE) gapped up before the market opened on Thursday . The stock had previously closed at $16.73, but opened at $17.97. uniQure shares last traded at $18.6430, with a volume of 565,211 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on QURE shares. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Stifel Nicolaus set a $14.00 target price on shares of uniQure in a report on Monday, March 2nd. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Leerink Partners restated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Trading Up 21.0%

The business’s fifty day moving average is $16.83 and its 200-day moving average is $26.06. The stock has a market capitalization of $1.27 billion, a PE ratio of -5.95 and a beta of 0.75. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. As a group, analysts anticipate that uniQure N.V. will post -3.6 EPS for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 14,581 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the sale, the chief executive officer owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 49,396 shares of company stock worth $722,734. 4.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Institutional investors have recently bought and sold shares of the business. Private Trust Co. NA purchased a new stake in uniQure during the third quarter worth approximately $28,000. Torren Management LLC purchased a new stake in uniQure during the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc purchased a new stake in uniQure during the fourth quarter worth approximately $48,000. Finally, Smartleaf Asset Management LLC purchased a new stake in uniQure during the fourth quarter worth approximately $48,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.